Scinopharm Taiwan Ltd, based in Taiwan, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
They are recognized for A leading process R&D and API Manufacturing service provider to the Global Pharmaceutical Industry.
One of their notable products is PALBOCICLIB, with a corresponding US DMF Number 32925.
Remarkably, this DMF maintains an Active status since its submission on July 16, 2018, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of May 31, 2019, and payment made on September 27, 2018, indicating their dedication to facilitating drug approvals, Categorized as Type II